As of Aug 18
| -0.15 / -1.99%|
The 3 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 34.00, with a high estimate of 41.00 and a low estimate of 11.00. The median estimate represents a +359.46% increase from the last price of 7.40.
The current consensus among 4 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.